241 related articles for article (PubMed ID: 9748133)
21. Lipid peroxidation, total antioxidant status, and total thiol levels predict overall survival in patients with oral squamous cell carcinoma.
Patel BP; Rawal UM; Dave TK; Rawal RM; Shukla SN; Shah PM; Patel PS
Integr Cancer Ther; 2007 Dec; 6(4):365-72. PubMed ID: 18048884
[TBL] [Abstract][Full Text] [Related]
22. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
23. P53 auto-antibodies in the sera of patients with oral squamous cell carcinoma.
Friedrich RE; Bartel-Friedrich S; Plambeck K; Bahlo M; Klapdor R
Anticancer Res; 1997; 17(4B):3183-4. PubMed ID: 9329632
[TBL] [Abstract][Full Text] [Related]
24. Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer.
Ralhan R; Agarwal S; Mathur M; Wasylyk B; Srivastava A
Clin Cancer Res; 2000 Jun; 6(6):2440-7. PubMed ID: 10873097
[TBL] [Abstract][Full Text] [Related]
25. Correlation between p53 gene mutations and circulating antibodies in betel- and tobacco-consuming North Indian population.
Ralhan R; Agarwal S; Nath N; Mathur M; Wasylyk B; Srivastava A
Oral Oncol; 2001 Apr; 37(3):243-50. PubMed ID: 11287278
[TBL] [Abstract][Full Text] [Related]
26. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.
Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR
Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393
[TBL] [Abstract][Full Text] [Related]
27. Serum circulating immune complexes as prognostic indicators in premalignant and malignant lesions of oral cavity during and following radiotherapy.
Rai S; Mody RN
J Cancer Res Ther; 2012 Jan; 8 Suppl 1():S116-22. PubMed ID: 22322729
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
29. MGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor prognosis.
Sawhney M; Rohatgi N; Kaur J; Gupta SD; Deo SV; Shukla NK; Ralhan R
Oral Oncol; 2007 May; 43(5):515-22. PubMed ID: 16996781
[TBL] [Abstract][Full Text] [Related]
30. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
[TBL] [Abstract][Full Text] [Related]
31. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
[TBL] [Abstract][Full Text] [Related]
32. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
33. Alteration of autoantibodies against p53 in Taiwanese lung cancer patients undergoing chemotherapy.
Lee YL; Shih CM; Chiou HL; Shiau MY; Chang GC; Chang YH
Clin Chim Acta; 2004 Nov; 349(1-2):87-96. PubMed ID: 15469860
[TBL] [Abstract][Full Text] [Related]
34. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
[TBL] [Abstract][Full Text] [Related]
35. Survivin expression predicts poorer prognosis in patients with areca quid chewing-related oral squamous cell carcinoma in Taiwan.
Lin CY; Hung HC; Kuo RC; Chiang CP; Kuo MY
Oral Oncol; 2005 Jul; 41(6):645-54. PubMed ID: 15927524
[TBL] [Abstract][Full Text] [Related]
36. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck.
Lavieille JP; Lubin R; Soussi T; Reyt E; Brambilla C; Riva C
Anticancer Res; 1996; 16(4C):2385-8. PubMed ID: 8816839
[TBL] [Abstract][Full Text] [Related]
37. Role of p53 and bcl2 as markers of vitamin A response in premalignant lesions of the oral cavity.
Varma D; Gupta S; Mandal AK
Indian J Pathol Microbiol; 2007 Jan; 50(1):15-7. PubMed ID: 17474247
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical study of p53 and angiogenesis in benign and preneoplastic oral lesions and oral squamous cell carcinoma.
Abbas NF; Labib El-Sharkawy S; Abbas EA; Abdel Monem El-Shaer M
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):385-90. PubMed ID: 17321451
[TBL] [Abstract][Full Text] [Related]
39. p53 Antibodies in the sera of patients with various types of cancer: a review.
Soussi T
Cancer Res; 2000 Apr; 60(7):1777-88. PubMed ID: 10766157
[TBL] [Abstract][Full Text] [Related]
40. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
